JP2007530652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530652A5 JP2007530652A5 JP2007505632A JP2007505632A JP2007530652A5 JP 2007530652 A5 JP2007530652 A5 JP 2007530652A5 JP 2007505632 A JP2007505632 A JP 2007505632A JP 2007505632 A JP2007505632 A JP 2007505632A JP 2007530652 A5 JP2007530652 A5 JP 2007530652A5
- Authority
- JP
- Japan
- Prior art keywords
- monohydrochloride
- crystalline
- compound
- endothermic
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 16
- 238000000034 method Methods 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- -1 3-formamido-4-hydroxyphenyl Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407521A GB0407521D0 (en) | 2004-04-02 | 2004-04-02 | Chemical process |
| GB0411688A GB0411688D0 (en) | 2004-05-25 | 2004-05-25 | Chemical process |
| US57446704P | 2004-05-26 | 2004-05-26 | |
| PCT/GB2005/001241 WO2005095328A1 (en) | 2004-04-02 | 2005-03-30 | Chemical process and new crystalline form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530652A JP2007530652A (ja) | 2007-11-01 |
| JP2007530652A5 true JP2007530652A5 (https=) | 2008-03-21 |
Family
ID=34963396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505632A Pending JP2007530652A (ja) | 2004-04-02 | 2005-03-30 | 化学物質、調製方法、及び、新規結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7846973B2 (https=) |
| EP (1) | EP1730104A1 (https=) |
| JP (1) | JP2007530652A (https=) |
| AR (1) | AR052301A1 (https=) |
| AU (1) | AU2005227733A1 (https=) |
| BR (1) | BRPI0509382A (https=) |
| CA (1) | CA2561400A1 (https=) |
| IL (1) | IL178064A0 (https=) |
| MA (1) | MA28558B1 (https=) |
| NO (1) | NO20064884L (https=) |
| PE (1) | PE20060678A1 (https=) |
| TW (1) | TW200536814A (https=) |
| WO (1) | WO2005095328A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066907A1 (en) * | 2004-12-21 | 2006-06-29 | Glaxo Group Limited | Pharmaceutical formulations |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| IT1399912B1 (it) * | 2010-04-29 | 2013-05-09 | Lundbeck Pharmaceuticals Italy S Pa | Processo di preparazione di ritodrina cloridrato. |
| JP5645762B2 (ja) * | 2010-06-29 | 2014-12-24 | 日本ポリプロ株式会社 | ポリオレフィンの結晶性分布分析方法およびその装置 |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
| US4353656A (en) * | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| AU591152B2 (en) * | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US5552438A (en) * | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5495054A (en) * | 1994-05-31 | 1996-02-27 | Sepracor, Inc. | Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| GB9700226D0 (en) * | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US6632666B2 (en) * | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| AR040661A1 (es) * | 2002-07-26 | 2005-04-13 | Theravance Inc | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 |
| JP2006503108A (ja) | 2002-09-16 | 2006-01-26 | グラクソ グループ リミテッド | ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用 |
| TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
-
2005
- 2005-03-30 CA CA002561400A patent/CA2561400A1/en not_active Abandoned
- 2005-03-30 WO PCT/GB2005/001241 patent/WO2005095328A1/en not_active Ceased
- 2005-03-30 EP EP05729685A patent/EP1730104A1/en not_active Withdrawn
- 2005-03-30 AU AU2005227733A patent/AU2005227733A1/en not_active Abandoned
- 2005-03-30 JP JP2007505632A patent/JP2007530652A/ja active Pending
- 2005-03-30 BR BRPI0509382-1A patent/BRPI0509382A/pt not_active IP Right Cessation
- 2005-03-30 US US10/599,145 patent/US7846973B2/en not_active Expired - Fee Related
- 2005-03-31 PE PE2005000372A patent/PE20060678A1/es not_active Application Discontinuation
- 2005-03-31 TW TW094110351A patent/TW200536814A/zh unknown
- 2005-03-31 AR ARP050101278A patent/AR052301A1/es not_active Application Discontinuation
-
2006
- 2006-09-13 IL IL178064A patent/IL178064A0/en unknown
- 2006-10-26 NO NO20064884A patent/NO20064884L/no not_active Application Discontinuation
- 2006-10-30 MA MA29421A patent/MA28558B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101412700B (zh) | 非布司他的晶型及其制备方法 | |
| WO2011095059A1 (zh) | 达沙替尼多晶型物及其制备方法和药物组合物 | |
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| DK2547649T3 (en) | Agomelatine Hydrochloride Hydrate and its Preparation | |
| CN101528762A (zh) | 5-氨基-3-(2′,3′-二-O-乙酰基-β-D-呋喃核糖基)-3H-噻唑并[4,5-D]嘧啶-2-酮的马来酸盐的结晶A和B形式 | |
| JP2011506374A (ja) | テノホビルジソプロキシルの固形物 | |
| JP2007530652A5 (https=) | ||
| JP2008513358A5 (https=) | ||
| JP2009535340A5 (https=) | ||
| JP2020517611A5 (https=) | ||
| CN110650963A (zh) | (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂*-9-基)氨基)丙酰胺的多晶型物和固体形式及其制备方法 | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| US11028069B2 (en) | Salt of substituted piperidine compound | |
| BRPI0111140B1 (pt) | Forma polimórfica, uso da mesma, e, composição farmacêutica | |
| WO2012022240A1 (zh) | 一种厄洛替尼碱的新晶型及其制备方法 | |
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
| CN102675395B (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
| CN112119073A (zh) | 阿贝西尼的固态形式、其用途和制备 | |
| JP2018024636A (ja) | ［（２ｒ，３ｓ，４ｒ，５ｒ）−５−（６−（シクロペンチルアミノ）−９ｈ−プリン−９−イル）−３，４−ジヒドロキシテトラヒドロフラン−２−イル］メチルナイトレートの無水多形体及びその製造方法 | |
| RU2006134478A (ru) | Химический способ и новая кристаллическая форма | |
| CN116199729B (zh) | 乙酰氨基阿维菌素晶型b及其制备方法 | |
| CN103408400B (zh) | 一种肌醇晶体及其制备方法和用途 | |
| CN109963855B (zh) | 一种btk激酶抑制剂的结晶形式及制备方法 | |
| CN106478603B (zh) | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 |